文献速递浆细胞疾病造血干细胞移植与细胞治疗

自体造血干细胞移植对四联诱导治疗多发性骨髓瘤中二代测序量化疾病负荷的影响

Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
PubMed 文献 · Am J Hematol · 2022-07-06

本研究在采用四联诱导、自体造血干细胞移植(AHCT)及MRD适应性巩固治疗的临床试验中,对123例新诊断多发性骨髓瘤患者进行二代测序(NGS)MRD连续评估。109例接受AHCT并完成移植前后MRD检测,移植后MRD<10⁻⁵比例从诱导后的40%升至70%。诱导后仍MRD阳性的65例中54例(83%)移植后MRD负荷下降,中位降幅1.10 log10。

要点

  • 移植后MRD<10⁻⁵比例由诱导后40%升至70%。
  • 诱导后MRD阳性者中83%移植后MRD负荷下降,中位降幅1.10 log10。
  • 高危细胞遗传学异常是移植后MRD降幅>1 log10的唯一相关因素。

核心结论

  • 在四联诱导背景下,连续NGS MRD检测显示AHCT可进一步降低骨髓瘤疾病负荷,尤其在高危骨髓瘤患者中。

研究设计与样本

  • 研究纳入某临床试验中接受四联诱导、AHCT及MRD适应性巩固治疗的新诊断多发性骨髓瘤患者,共123例,其中109例接受AHCT并完成移植前后MRD评估。

主要发现

  • 123例中109例接受AHCT并有移植前后MRD评估;40%在诱导后达到MRD<10⁻⁵,AHCT后升至70%。
  • 诱导后仍MRD阳性的65例(60%)中,54例(83%)在AHCT后MRD负荷下降。
  • AHCT后MRD中位降幅为1.10 log10(范围,-1.26至3.41)。
  • 高危细胞遗传学异常(HRCA)患者AHCT后MRD负荷降幅更大(p = .02)。
  • 0、1和2+个HRCA患者的中位相对降幅分别为0.91 log10(范围,-0.75至2.14)、1.26 log10(范围,-0.21至3.26)和1.34 log10(范围,-1.28至3.41)。

关键数值与推荐

  • HRCA是AHCT后MRD负荷降幅大于1 log10的唯一相关因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incremental impact of autologous hematopoietic cell transplantation (AHCT) on disease burden with quadruplet induction in newly diagnosed multiple myeloma (NDDM) can be reappraised with the serial assessment of minimal residual disease (MRD). We describe the impact of AHCT on MM burden assessed by next-generation sequencing (NGS) for patients enrolled in a clinical trial utilizing quadruplet induction, AHCT, followed by MRD-adapted consolidation. We describe quantitative changes in MRD burden with AHCT and explore patient and disease features influencing the magnitude of MRD reduction with AHCT. Among 123 included patients, 109 underwent AHCT and had MRD assessment pre and post AHCT. Forty percent achieved MRD < 10-5 post-induction, increasing to 70% after AHCT. Of the 65 patients (60%) who remained MRD positive post-induction, 54 (83%) had a reduction in MRD burden with AHCT. The median reduction in MRD with AHCT was 1.10 log10 (range, -1.26 to 3.41). Patients with high-risk cytogenetic abnormalities (HRCA) had greater reduction in MRD burden (p = .02) after AHCT. Median relative reduction was 0.91 log10 (range, -0.75 to 2.14), 1.26 log10 (range, -0.21 to 3.26) and 1.34 log10 (range, -1.28 to 3.41) for patients with 0, 1 and 2+ HRCA, respectively. The presence of HRCA was the only factor associated with greater than 1 log10 reduction in MRD burden with AHCT. Serial NGS MRD demonstrates the incremental effect of AHCT in MM marrow burden in the context of quadruplet induction, particularly in high-risk MM.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bal S, Dhakal B, Silbermann RW, et al. Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy. Am J Hematol. 2022. PMID: 35731911. doi:10.1002/ajh.26640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。